HAVRIX is a Intramuscular Injection, Suspension in the Vaccine category. It is labeled and distributed by Glaxosmithkline Biologicals Sa. The primary component is Hepatitis A Virus Strain Hm175 Antigen (formaldehyde Inactivated).
Product ID | 58160-826_2e1feba0-92d3-4d43-974b-3e8a4ef71f00 |
NDC | 58160-826 |
Product Type | Vaccine |
Proprietary Name | HAVRIX |
Generic Name | Hepatitis A Vaccine |
Dosage Form | Injection, Suspension |
Route of Administration | INTRAMUSCULAR |
Marketing Start Date | 2007-04-13 |
Marketing Category | BLA / BLA |
Application Number | BLA103475 |
Labeler Name | GlaxoSmithKline Biologicals SA |
Substance Name | HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED) |
Active Ingredient Strength | 1440 [iU]/mL |
Pharm Classes | Actively Acquired Immunity [PE], Hepatitis A Vaccines [CS], Inactivated Hepatitis A Virus Vaccine [EPC], Vaccines, Inactivated [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2007-04-13 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Billing Unit | ML |
Marketing Start Date | 2011-01-21 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Billing Unit | ML |
Marketing Start Date | 2009-11-21 |
Marketing End Date | 2012-02-25 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Marketing Start Date | 2012-02-25 |
Marketing End Date | 2020-02-24 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Marketing Start Date | 2012-02-25 |
Marketing End Date | 2020-02-24 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Billing Unit | ML |
Marketing Start Date | 2010-08-03 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Billing Unit | ML |
Marketing Start Date | 2007-04-13 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Marketing Start Date | 2007-04-13 |
Marketing End Date | 2013-02-08 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Marketing Start Date | 2007-04-13 |
Marketing End Date | 2013-02-08 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Marketing Start Date | 2007-04-13 |
Marketing End Date | 2013-06-17 |
Marketing Category | BLA |
Application Number | BLA103475 |
Product Type | VACCINE |
Billing Unit | ML |
Marketing Start Date | 2007-04-13 |
Ingredient | Strength |
---|---|
HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED) | 1440 [iU]/mL |
NDC | Brand Name | Generic Name |
---|---|---|
50090-1502 | HAVRIX | Hepatitis A Vaccine |
55045-3841 | HAVRIX | Hepatitis A Vaccine |
58160-825 | HAVRIX | Hepatitis A Vaccine |
58160-826 | HAVRIX | Hepatitis A Vaccine |
68258-8912 | HAVRIX | Hepatitis A Vaccine |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
HAVRIX 74042847 1701341 Live/Registered |
SmithKline Biologicals, S.A. 1990-03-26 |